AAM
MRNA icon

Advisors Asset Management’s Moderna MRNA Stock Holding History

Advisors Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,346
Closed -$221K – 1458
2026
Q1 		$221K Sell
4,346
-442
-9% -$20.6K ﹤0.01% 1132
2025
Q4 		$141K Sell
4,788
-129
-3% -$3.5K ﹤0.01% 1180
2025
Q3 		$127K Sell
4,917
-63
-1% -$1.76K ﹤0.01% 1190
2025
Q2 		$137K Sell
4,980
-70
-1% -$1.84K ﹤0.01% 1161
2025
Q1 		$143K Sell
5,050
-236
-4% -$8.38K ﹤0.01% 1144
2024
Q4 		$220K Buy
5,286
+546
+12% +$26.1K ﹤0.01% 1104
2024
Q3 		$317K Buy
4,740
+971
+26% +$89.1K 0.01% 1030
2024
Q2 		$448K Buy
3,769
+2,134
+131% +$270K 0.01% 929
2024
Q1 		$174K Sell
1,635
-95
-5% -$9.58K ﹤0.01% 1157
2023
Q4 		$172K Sell
1,730
-4,688
-73% -$394K ﹤0.01% 1134
2023
Q3 		$663K Sell
6,418
-750
-10% -$83.7K 0.01% 830
2023
Q2 		$871K Sell
7,168
-2,050
-22% -$273K 0.02% 787
2023
Q1 		$1.42M Sell
9,218
-629
-6% -$104K 0.03% 629
2022
Q4 		$1.77M Sell
9,847
-4,136
-30% -$676K 0.04% 540
2022
Q3 		$1.65M Buy
13,983
+338
+2% +$51.3K 0.03% 561
2022
Q2 		$1.95M Buy
13,645
+2,803
+26% +$401K 0.04% 521
2022
Q1 		$1.87M Buy
10,842
+2,532
+30% +$426K 0.03% 608
2021
Q4 		$2.11M Buy
8,310
+1,903
+30% +$556K 0.03% 591
2021
Q3 		$2.47M Buy
6,407
+488
+8% +$180K 0.04% 530
2021
Q2 		$1.39M Buy
5,919
+1,031
+21% +$184K 0.02% 715
2021
Q1 		$640K Buy
4,888
+1,590
+48% +$230K 0.01% 958
2020
Q4 		$345K Buy
3,298
+362
+12% +$36.6K 0.01% 1079
2020
Q3 		$208K Sell
2,936
-6,848
-70% -$477K ﹤0.01% 1171
2020
Q2 		$628K Buy
9,784
+6,437
+192% +$353K 0.01% 827
2020
Q1 		$100K Sell
3,347
-63
-2% -$1.45K ﹤0.01% 1227
2019
Q4 		$66.7K Buy
3,410
+11
+0.3% +$195 ﹤0.01% 1374
2019
Q3 		$54.1K Sell
3,399
-7,549
-69% -$112K ﹤0.01% 1389
2019
Q2 		$160K Buy
+10,948
New +$235K ﹤0.01% 1223

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Advisors Asset Management's MRNA Position: Q2 2026 in Review

Advisors Asset Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 4,346 shares — an estimated $221K sold.

Advisors Asset Management first reported a position in MRNA in Q2 2019 and held it in 28 quarters. The position peaked at $2.47M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Advisors Asset Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Advisors Asset Management sold 4,346 Moderna shares in Q2 2026, an estimated $221K.
  • Advisors Asset Management first reported a position in Moderna in Q2 2019 and held it in 28 quarters.
  • Advisors Asset Management's Moderna position peaked at $2.47M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.